Effect of bioengineering lacticin 3147 lanthionine bridges on specific activity and resistance to heat and proteases

Chemistry and Biology

Volumn 17, Issue 10, 2010, Pages 1151-1160

  Suda, Srinivas ^a   Westerbeek, Alja ^a   O'Connor, Paula M ^b,c   Ross, R Paul ^b,c   Hill, Colin ^a,c   Cotter, Paul D ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIINFECTIVE AGENT; BACTERIOCIN; BETA METHYLLANTHIONINE; BETA-METHYLLANTHIONINE; DRUG DERIVATIVE; LACTICIN 481; LANTHIONINE; PEPTIDE HYDROLASE; SULFIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BIOENGINEERING; CHEMISTRY; HEAT; MASS SPECTROMETRY; METABOLISM;

ALANINE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIOCINS; BIOENGINEERING; HOT TEMPERATURE; PEPTIDE HYDROLASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SULFIDES;

EID: 78049380526     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.08.011     Document Type: Article

References (43)

1. G. Bierbaum, C. Szekat, M. Josten, C. Heidrich, C. Kempter, G. Jung, and H.G. Sahl Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5 Appl. Environ. Microbiol. 62 1996 385 392
2. E. Breukink, and B. de Kruijff The lantibiotic nisin, a special case or not? Biochim. Biophys. Acta 1462 1999 223 234
3. E. Breukink, I. Wiedemann, C. van Kraaij, O.P. Kuipers, H. Sahl, and B. de Kruijff Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic Science 286 1999 2361 2364
4. H. Brotz, M. Josten, I. Wiedemann, U. Schneider, F. Gotz, G. Bierbaum, and H.G. Sahl Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics Mol. Microbiol. 30 1998 317 327
5. W. Brumfitt, M.R. Salton, and J.M. Hamilton-Miller Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci J. Antimicrob. Chemother. 50 2002 731 734
6. S. Chatterjee, S.J. Lad, M.S. Phansalkar, R.H. Rupp, B.N. Ganguli, H.W. Fehlhaber, and H. Kogler Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization J. Antibiot. (Tokyo) 45 1992 832 838
7. C. Chatterjee, M. Paul, L. Xie, and W.A. van der Donk Biosynthesis and mode of action of lantibiotics Chem. Rev. 105 2005 633 684
8. C. Chatterjee, G.C. Patton, L. Cooper, M. Paul, and W.A. van der Donk Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase Chem. Biol. 13 2006 1109 1117
9. P. Chen, J. Novak, M. Kirk, S. Barnes, F. Qi, and P.W. Caufield Structure-activity study of the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement strategy Appl. Environ. Microbiol. 64 1998 2335 2340
10. L.E. Cooper, A.L. McClerren, A. Chary, and W.A. van der Donk Structure-activity relationship studies of the two-component lantibiotic haloduracin Chem. Biol. 15 2008 1035 1045
11. P.D. Cotter, C. Hill, and R.P. Ross A food-grade approach for functional analysis and modification of native plasmids in Lactococcus lactis Appl. Environ. Microbiol. 69 2003 702 706
12. P.D. Cotter, C. Hill, and R.P. Ross Bacterial lantibiotics: strategies to improve therapeutic potential Curr. Protein Pept. Sci. 6 2005 61 75
13. P.D. Cotter, P.M. O'Connor, L.A. Draper, E.M. Lawton, L.H. Deegan, C. Hill, and R.P. Ross Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147 Proc. Natl. Acad. Sci. USA 102 2005 18584 18589
14. P.D. Cotter, L.H. Deegan, E.M. Lawton, L.A. Draper, P.M. O'Connor, C. Hill, and R.P. Ross Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design Mol. Microbiol. 62 2006 735 747
15. D. Field, B. Collins, P.D. Cotter, C. Hill, and R.P. Ross A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities J. Mol. Microbiol. Biotechnol. 13 2007 226 234
16. D. Field, P.M. Connor, P.D. Cotter, C. Hill, and R.P. Ross The generation of nisin variants with enhanced activity against specific gram-positive pathogens Mol. Microbiol. 69 2008 218 230
17. M. Galvin, C. Hill, and R.P. Ross Lacticin 3147 displays activity in buffer against gram-positive bacterial pathogens which appear insensitive in standard plate assays Lett. Appl. Microbiol. 28 1999 355 358
18. G.E. Gardiner, M.C. Rea, B. O'Riordan, P. O'Connor, S.M. Morgan, P.G. Lawlor, P.B. Lynch, M. Cronin, R.P. Ross, and C. Hill Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract Appl. Environ. Microbiol. 73 2007 7103 7109
19. S.T. Hsu, E. Breukink, G. Bierbaum, H.G. Sahl, B. de Kruijff, R. Kaptein, N.A. van Nuland, and A.M. Bonvin NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity J. Biol. Chem. 278 2003 13110 13117
20. Hurst, A. (1981). Nisin. Advances in Applied Microbiology, Volume 27, D. Perlman and A.I. Laskin, eds. (New York: Academic Press), pp. 85-123.
21. L.D. Kluskens, S.A. Nelemans, R. Rink, L. de Vries, A. Meter-Arkema, Y. Wang, T. Walther, A. Kuipers, G.N. Moll, and M. Haas Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog J. Pharmacol. Exp. Ther. 328 2009 849 854
22. D. Kruszewska, H.G. Sahl, G. Bierbaum, U. Pag, S.O. Hynes, and A. Ljungh Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model J. Antimicrob. Chemother. 54 2004 648 653
23. E.M. Lawton, R.P. Ross, C. Hill, and P.D. Cotter Two-peptide lantibiotics: a medical perspective Mini Rev. Med. Chem. 7 2007 1236 1247
24. N.I. Martin, T. Sprules, M.R. Carpenter, P.D. Cotter, C. Hill, R.P. Ross, and J.C. Vederas Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity Biochemistry 43 2004 3049 3056
25. O. McAuliffe, C. Hill, and R.P. Ross Each peptide of the two-component lantibiotic lacticin 3147 requires a separate modification enzyme for activity Microbiology 146 2000 2147 2154
26. M.A. Navaratna, H.G. Sahl, and J.R. Tagg Two-component anti-Staphylococcus aureus lantibiotic activity produced by Staphylococcus aureus C55 Appl. Environ. Microbiol. 64 1998 4803 4808
27. E.B. O'Connor, P.D. Cotter, P. O'Connor, O. O'Sullivan, J.R. Tagg, R.P. Ross, and C. Hill Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity BMC Microbiol. 7 2007 24
28. G. Osapay, L. Prokai, H.S. Kim, K.F. Medzihradszky, D.H. Coy, G. Liapakis, T. Reisine, G. Melacini, Q. Zhu, and S.H. Wang Lanthionine- somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies J. Med. Chem. 40 1997 2241 2251
29. U. Pag, and H.G. Sahl Multiple activities in lantibiotics-models for the design of novel antibiotics? Curr. Pharm. Des. 8 2002 815 833
30. C. Piper, P.D. Cotter, R.P. Ross, and C. Hill Discovery of medically significant lantibiotics Curr. Drug Discov. Technol. 6 2009 1 18
31. C. Piper, L.A. Draper, P.D. Cotter, R.P. Ross, and C. Hill A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species J. Antimicrob. Chemother. 64 2009 546 551
32. M.C. Rea, E. Clayton, P.M. O'Connor, F. Shanahan, B. Kiely, R.P. Ross, and C. Hill Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains J. Med. Microbiol. 56 2007 940 946
33. Y. Rew, S. Malkmus, C. Svensson, T.L. Yaksh, N.N. Chung, P.W. Schiller, J.A. Cassel, R.N. DeHaven, J.P. Taulane, and M. Goodman Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands J. Med. Chem. 45 2002 3746 3754
34. R. Rink, A. Arkema-Meter, I. Baudoin, E. Post, A. Kuipers, S.A. Nelemans, M.H. Akanbi, and G.N. Moll To protect peptide pharmaceuticals against peptidases J. Pharmacol. Toxicol. Methods 61 2010 210 218
35. M.P. Ryan, M.C. Rea, C. Hill, and R.P. Ross An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147 Appl. Environ. Microbiol. 62 1996 612 619
36. M.P. Ryan, J. Flynn, C. Hill, R.P. Ross, and W.J. Meaney The natural food grade inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental challenge with Streptococcus dysgalactiae in nonlactating dairy cows J. Dairy Sci. 82 1999 2625 2631 (Pubitemid 129545912)
37. M.P. Ryan, R.W. Jack, M. Josten, H.G. Sahl, G. Jung, R.P. Ross, and C. Hill Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147 J. Biol. Chem. 274 1999 37544 37550
38. K. Shioya, Y. Harada, J.I. Nagao, J. Nakayama, and K. Sonomoto Characterization of modification enzyme NukM and engineering of a novel thioether bridge in lantibiotic nukacin ISK-1 Appl. Microbiol. Biotechnol. 86 2009 891 899
39. I. Wiedemann, T. Bottiger, R.R. Bonelli, A. Wiese, S.O. Hagge, T. Gutsmann, U. Seydel, L. Deegan, C. Hill, and P. Ross The mode of action of the lantibiotic lacticin 3147-a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II Mol. Microbiol. 61 2006 285 296
40. J.M. Willey, and W.A. van der Donk Lantibiotics: peptides of diverse structure and function Annu. Rev. Microbiol. 61 2007 477 501
41. J. Wu Disulfide bond mapping by cyanylation-induced cleavage and mass spectrometry Methods Mol. Biol. 446 2008 1 20
42. J. Wu, and J.T. Watson Optimization of the cleavage reaction for cyanylated cysteinyl proteins for efficient and simplified mass mapping Anal. Biochem. 258 1998 268 276
43. L. Xie, and W.A. van der Donk Post-translational modifications during lantibiotic biosynthesis Curr. Opin. Chem. Biol. 8 2004 498 507